
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical has raised its long-term net sales compound annual growth rate (CAGR) target to 6.5%-7.5%, reflecting a positive outlook for sustained growth in its core markets. The company reported adjusted EBITDA of $23.9 million for the latest quarter, representing a year-over-year increase and exceeding consensus expectations, alongside an adjusted EBITDA margin expansion. Additionally, significant growth in key segments was noted, with the Spine Fixation segment growing by 12% and the Bone Growth Therapies increasing by 9%, further supported by the anticipated FDA approval of AccelStim 2.0, indicating robust market potential.
Bears say
Orthofix Medical Inc. is facing a negative outlook primarily due to the recent discontinuation of its M6-C and M6-L artificial disc product lines, which are projected to result in a loss of $23.4 million in 2024 sales, thereby impacting EBITDA margins negatively. The company’s strategic shift towards spinal fixation and deformity correction, although aimed at addressing demand issues, has raised concerns regarding the integration risk associated with its merger with SeaSpine and the ability to maintain sales momentum amidst significant competition from better-financed rivals. Additionally, potential regulatory and legal challenges, along with evolving reimbursement rates in the U.S. healthcare landscape, pose considerable risks that could further hinder Orthofix's growth and profitability in the near future.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares